{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:26:41Z","timestamp":1773275201323,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>\n            Although acute administration of urocortin 2 has beneficial actions in heart failure, the integrated hemodynamic, hormonal, and renal effects of sustained urocortin 2 treatment in this disease have not been investigated. In the current study, we administered a 4-day infusion of a vehicle control (0.9% saline; n=6) or urocortin 2 (0.75 \u03bcg\/kg per hour; n=6) to sheep with pacing-induced heart failure. Compared with time-matched controls, infusion of urocortin 2 produced rapid (30-minute) and persistent (4-day) improvements in cardiac contractility (day 4: control 905\u00b173 versus urocortin 2 1424\u00b1158 mm Hg\/s;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) and output (2.6\u00b10.1 versus 3.8\u00b10.3 L\/min;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001), together with reductions in left atrial pressure (28\u00b11 versus 12\u00b11 mm Hg;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) and peripheral resistance (30\u00b12 versus 20\u00b12 mm Hg\/L per min;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). In contrast, urocortin 2\u2013induced falls in mean arterial pressure were not established until the second day (day 4: 74\u00b12 versus 72\u00b12 mm Hg;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05). Prolonged urocortin 2 administration was associated with sustained (days 0 to 4) declines in plasma renin activity (day 4: 1.33\u00b10.27 versus 0.73\u00b10.20 nmol\/L per hour;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001), aldosterone (970\u00b1383 versus 396\u00b196 pmol\/L;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05), vasopressin (2.4\u00b10.8 versus 1.3\u00b10.1 pmol\/L;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05), endothelin 1 (7.2\u00b10.7 versus 4.5\u00b10.4 pmol\/L;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.01), and atrial (269\u00b127 versus 150\u00b119 pmol\/L;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) and B-type (65\u00b19 versus 29\u00b16 pmol\/L;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) natriuretic peptides, as well as an acute transient rise in plasma cortisol (day 1:\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). Chronic urocortin 2 also persistently augmented urinary sodium (day 4: 4-fold increase;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) and creatinine (1.4-fold;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001) excretion and creatinine clearance (1.5-fold;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.01) compared with control. Food consumption was temporarily suppressed (\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05). In conclusion, 4-day urocortin 2 administration induces sustained improvements in hemodynamics and renal function, in association with inhibition of multiple vasoconstrictor\/volume-retaining systems. These findings support the therapeutic potential for urocortin 2 in heart failure.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.111.173203","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T02:42:01Z","timestamp":1304390521000},"page":"1136-1144","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Prolonged Urocortin 2 Administration in Experimental Heart Failure"],"prefix":"10.1161","volume":"57","author":[{"given":"Miriam T.","family":"Rademaker","sequence":"first","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Charles","sequence":"additional","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh J.","family":"Ellmers","sequence":"additional","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynley K.","family":"Lewis","sequence":"additional","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Gary","family":"Nicholls","sequence":"additional","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[{"name":"From the Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/378287a0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/87936"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705985"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.48.1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307324101"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02170-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.561308"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20050079"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm340"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi227"},{"key":"e_1_3_4_12_2","first-page":"149","article-title":"Gateways to clinical trials","volume":"30","author":"Moral MA","year":"2008","unstructured":"Moral MA, Tomillero A. Gateways to clinical trials. Methods Findings Exp Clin Pharmacol. 2008;30: 149\u2013171.","journal-title":"Methods Findings Exp Clin Pharmacol"},{"key":"e_1_3_4_13_2","first-page":"H1052","article-title":"Neurohumoral changes during the onset and offset of ovine heart failure: Role of ANP","volume":"256","author":"Fitzpatrick MA","year":"1989","unstructured":"Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: Role of ANP. Am J Physiol. 1989;256: H1052\u2013H1059.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_14_2","first-page":"H594","article-title":"Natriuretic peptide responses to acute and chronic pacing in sheep","volume":"270","author":"Rademaker MT","year":"1996","unstructured":"Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic pacing in sheep. Am J Physiol. 1996;270: H594\u2013H602.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00377.2007"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.125211"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi351"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-08-0505"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.01.022"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1139\/Y09-119"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1976.56.1.1"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20070364"},{"key":"e_1_3_4_23_2","first-page":"278","article-title":"Angiotension-(1-7) and antihypertensive mechanisms","volume":"11","author":"Ferrario CM","year":"1998","unstructured":"Ferrario CM. Angiotension-(1-7) and antihypertensive mechanisms. J Nephrol. 1998;11: 278\u2013283.","journal-title":"J Nephrol"},{"key":"e_1_3_4_24_2","first-page":"276","volume-title":"Principles and Practice of Endocrinology and Metabolism","author":"Robertson GL","year":"2001","unstructured":"Robertson GL. Physiology of vasopressin, oxytocin, and thirst. In: Principles and Practice of Endocrinology and Metabolism. 3rd ed. , Kenneth Becker ed. Lippincott Williams & Wilkins: Philadelphia, PA.2001; 276\u2013285.","edition":"3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040253"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.05.021"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.075259"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/74263"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(00)00077-X"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.05.023"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.05.024"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000059433"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2007.10.008"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.111.173203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:38:37Z","timestamp":1715593117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.111.173203"}},"subtitle":["Sustained Hemodynamic, Endocrine, and Renal Effects"],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.111.173203"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.111.173203","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"2011-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}